The Quality Digest is a recap of content aimed at advancing clinical care and excellence and keeping you informed about the latest regulations.
Influenza and Adult Immunization Guide Updated for 2023-24
We are pleased to release PharMerica's 2023-2024 Influenza and Adult Immunization Guide! Inside, you'll find materials covering clinical and regulatory issues with respect to influenza and other select vaccine-preventable diseases, including:
CMS requirements for influenza, pneumococcal, and COVID-19 vaccines
CDC guidance on influenza vaccines, antivirals, and managing outbreaks
Updated recommendations for influenza, pneumococcal, hepatitis B, and shingles vaccines
Recommendations for the two recently approved RSV vaccines
Essential documents for facility use such as Vaccine Information Statements (VIS), consent forms, and declination forms
Did You Know? Pneumococcal Disease and the 2023 CDC Pneumococcal Vaccine Guidance
This updated Did You Know guide provides a thorough overview of pneumococcal disease and current vaccination recommendations for adults 65 and over as well as immunocompromised adults aged 19-64.
Did You Know? RSV and Vaccination for Older Adults
Read our new Did You Know guide to learn about the signs and symptoms of RSV in older adults, medical conditions and other factors that confer increased risk, and current recommendations regarding the two recently approved vaccines.
Onco360 Offers Recently Approved Quizartinib (Vanflyta®) for Acute Myeloid Leukemia
Quizartinib (Vanflyta®) won FDA approval on July 24, 2023. It is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation and as maintenance monotherapy following consolidation chemotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication positive as detected by an FDA-approved test. Onco360 will have access to this medication as part of a limited distribution pharmacy network created by the drug manufacturer Daiichi Sankyo.